A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: Efimosfermin alfa
DRUG: Efimosfermin alfa
DRUG: Placebo

Sponsor

GlaxoSmithKline